Eli Lilly Hikes Mounjaro Price in UK by 170% for Private-Pay Patients
US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) announced on August 14, 2025, that...
Qihan Biotech’s QT-019B Gains FDA IND Approval for Autoimmune Diseases
Hangzhou Qihan Biotech Co., Ltd. announced that its self-developed universal dual-target CAR-T cell product, QT-019B,...
Novartis’ Ianalumab Shows Positive Results in Phase 3 Trials for ITP and Sjögren’s Disease
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced positive top-line results from the Phase 3 VAYHIT2...
Everest Medicines’ Velsipity NDA Accepted for Review in Taiwan
China-based Everest Medicines (HKG: 1952) announced that the New Drug Application (NDA) for its Velsipity...
Hualan Biological Gains NMPA Approval for Hib Vaccine Clinical Trials
Hualan Biological Engineering Inc., (SHE: 002007) announced that its freeze-dried Haemophilus influenzae type b (Hib)...
RemeGen Announces Positive Phase III Results for Telitacicept in Primary Sjögren’s Syndrome
China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based pharmaceutical firm, announced on August...
China Issues Guidelines for Medical Advertisement Identification, Clarifies Scenarios and Regulations
The State Administration for Market Regulation (SAMR), in collaboration with the National Health Commission (NHC)...
MSD Officially Launches Zerbaxa in China to Tackle Drug-Resistant Infections
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced on August 13, 2025, the...
Jiangsu Hengrui Establishes New Biopharmaceutical Unit to Strengthen Anesthesia and ICU Presence
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 14, 2025,...
Jiangsu Hengrui’s Combo Therapy Approved for Clinical Trials by NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 13, 2025,...
Henlius Biotech’s HLX04-O Accepted by NMPA for Wet AMD Treatment
Shanghai Henlius Biotech Inc. (HKG: 2696) announced on August 13, 2025, that the marketing authorization...
TYK Medicines’ Asandeutertinib Shows Promising Results in Phase II Trial for EGFR-Mutated NSCLC
China-based TYK Medicines, Inc. (HKG: 2410) announced on August 14, 2025, that the results of...
CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma
CANbridge Pharmaceuticals (HKG: 1228) announced on August 13, 2025, that it has entered into a...
Kangji Medical Proposes Privatization, Aiming to Delist from Hong Kong Stock Exchange
Kangji Medical Holdings Limited (HKG: 9997) has submitted a proposal to its shareholders regarding a...
Hengrui Pharmaceuticals Expands Hetrombopag Olamine’s Indication for ITP Patients
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced that the indication expansion for...
Ascletis Pharma Reports Positive Preclinical Results for ASC47 in Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) announced encouraging efficacy results from preclinical trials of ASC47,...
Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor
German pharmaceutical giant Bayer AG (ETR: BAYN) and Kumquat Biosciences Inc. jointly announced on August...
Sino Biopharmaceutical’s TQB3142 IND Application Accepted by China’s NMPA for Malignant Tumor Treatment
Sino Biopharmaceutical Limited (HKG: 1177) announced that the Investigational New Drug (IND) application for TQB3142,...
Novartis’ Leqvio Approved by FDA as Standalone Therapy for Hypercholesterolemia
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 12, 2025, that the U.S. Food...
HighTide Therapeutics Collaborates with IMB to Assess HTD1801 in T2DM with CKD
China-based HighTide Therapeutics, Inc. (HKG: 2511) announced the commencement of a collaborative project with the...